

	MET copy < 5(n=70)	MET copy>5(n=11) Table S1
Male	61(87.1%)	10(90.9%)
Female	9(12.9%)	1(9.1%)
ECOG performance status		
0	61(87.1%)	10(90.9%)
1	7(10.0%)	1(9.1%)
≥2	2(2.9%)	0
>60y	33(47.1%)	9(81.8%)
<60y	37(52.9%)	2(18.2%)
Adenocarcinoma	58(82.9%)	11(100%)
Squamous carcinoma	12(17.1%)	0
IIIB stage	6(8.6%)	0
IV stage	64(91.4%)	11(100%)
Former smoking	59(84.2%)	8(72.7%)
Median PFS(days)	174	85
PDL1 expression		
>50%	13(18.6%)	8(72.7%)
<50%	46(65.8%)	1(9.1%)
No PDL1 test	11(15.6%)	2(18.2%)
Lines of therapy		
First	21(30.0%)	4(36.3%)
Second	33(47.1%)	5(45.4%)
≥Second	16(22.9%)	2(18.3%)